3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
7
Hodgkin Disease
6
Lymphoma, Large B-Cell, Diffuse
5
Triple Negative Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Rhabdomyosarcoma
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Burkitt Lymphoma
3
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neuroblastoma
2
Multiple Myeloma
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Teratoma
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Sarcoma, Ewing
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Pain
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
pegfilgrastim
×
1 year
×
Clear all
No trials found.